Ocular Therapeutix, Inc. (OCUL)
NASDAQ: OCUL · Real-Time Price · USD
8.64
-0.14 (-1.59%)
Nov 21, 2024, 1:04 PM EST - Market open
Ocular Therapeutix Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for Ocular Therapeutix stock have an average target of 16.5, with a low estimate of 11 and a high estimate of 22. The average target predicts an increase of 90.97% from the current stock price of 8.64.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for OCUL stock from 8 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 4 | 4 | 4 | 4 | 5 | 5 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $14 → $15 | Strong Buy | Maintains | $14 → $15 | +73.61% | Nov 15, 2024 |
| Scotiabank | Scotiabank | Buy Initiates $22 | Buy | Initiates | $22 | +154.63% | Oct 16, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $14 | Strong Buy | Reiterates | $14 | +62.04% | Oct 16, 2024 |
| Baird | Baird | Buy Maintains $18 → $17 | Buy | Maintains | $18 → $17 | +96.76% | Aug 8, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $14 | Strong Buy | Reiterates | $14 | +62.04% | Aug 1, 2024 |
Financial Forecast
Revenue This Year
67.50M
from 58.44M
Increased by 15.49%
Revenue Next Year
76.48M
from 67.50M
Increased by 13.31%
EPS This Year
-1.20
from -1.02
EPS Next Year
-1.04
from -1.20
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 75.8M | 90.7M | 147.6M | ||
| Avg | 67.5M | 76.5M | 97.1M | ||
| Low | 61.3M | 64.3M | 73.5M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 29.7% | 34.3% | 93.0% | ||
| Avg | 15.5% | 13.3% | 27.0% | ||
| Low | 4.9% | -4.8% | -3.9% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | -0.92 | -0.86 | -0.47 |
| Avg | -1.20 | -1.04 | -1.05 |
| Low | -1.34 | -1.21 | -1.32 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.